{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:31:35Z","timestamp":1794047495870,"version":"4.8.0"},"reference-count":16,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"9","license":[{"start":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T00:00:00Z","timestamp":1742428800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"DOI":"10.3324\/haematol.2024.287095","type":"journal-article","created":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T04:20:27Z","timestamp":1742444427000},"page":"2203-2208","source":"Crossref","is-referenced-by-count":1,"title":["Doubling in median survival in patients diagnosed with multiple myeloma 2005-2019; a real-world study from the UK\u2019s Haematological Malignancy Research Network"],"prefix":"10.3324","volume":"110","author":[{"given":"Alexandra","family":"Smith","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Bagguley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eve","family":"Roman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Crouch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell","family":"Patmore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"De Tute","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andy","family":"Rawstron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordon","family":"Cook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frances","family":"Seymour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Parrish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2025,3,20]]},"reference":[{"key":"79105","doi-asserted-by":"crossref","unstructured":"Turesson I, Bjorkholm M, Blimark CH, Kristinsson S, Velez R, Landgren O. Rapidly changing myeloma epidemiology in the general population: increased incidence, older patients, and longer survival. Eur J Haematol. 2018; 101(2):237-244.","DOI":"10.1111\/ejh.13083"},{"key":"79106","doi-asserted-by":"crossref","unstructured":"Shah JJ, Abonour R, Gasparetto C. Analysis of common eligibility criteria of randomized controlled trials in newly diagnosed multiple myeloma patients and extrapolating outcomes. Clin Lymphoma Myeloma Leuk. 2017; 17(9):575-583.e2.","DOI":"10.1016\/j.clml.2017.06.013"},{"key":"79107","doi-asserted-by":"crossref","unstructured":"Richardson PG, San Miguel JF, Moreau P. Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting. Blood Cancer J. 2018; 8(11):109.","DOI":"10.1038\/s41408-018-0141-0"},{"key":"79108","doi-asserted-by":"crossref","unstructured":"Smith A, Howell D, Crouch S. Cohort profile: the Haematological Malignancy Research Network (HMRN); a UK population-based patient cohort. Int J Epidemiol. 2018; 47(3):700.","DOI":"10.1093\/ije\/dyy044"},{"key":"79109","doi-asserted-by":"crossref","unstructured":"Maringe C, Fowler H, Rachet B, Luque-Fernandez MA. Reproducibility, reliability and validity of population-based administrative health data for the assessment of cancer non-related comorbidities. PLoS One. 2017; 12(3):e0172814.","DOI":"10.1371\/journal.pone.0172814"},{"key":"79110","doi-asserted-by":"crossref","unstructured":"Gilbert T, Neuburger J, Kraindler J. Development and validation of a Hospital Frailty Risk Score focusing on older people in acute care settings using electronic hospital records: an observational study. Lancet. 2018; 391(10132):1775-1782.","DOI":"10.1016\/S0140-6736(18)30668-8"},{"key":"79111","doi-asserted-by":"crossref","unstructured":"Elliss-Brookes L, McPhail S, Ives A. Routes to diagnosis for cancer \u2013 determining the patient journey using multiple routine data sets. Br J Cancer. 2012; 107(8):1220-1226.","DOI":"10.1038\/bjc.2012.408"},{"key":"79112","doi-asserted-by":"crossref","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014; 15(12):e538-548.","DOI":"10.1016\/S1470-2045(14)70442-5"},{"key":"79113","doi-asserted-by":"crossref","unstructured":"Greipp PR, San Miguel J, Durie BGM. International staging system for multiple myeloma. J Clin Oncol. 2005; 23(15):3412-3420.","DOI":"10.1200\/JCO.2005.04.242"},{"key":"79114","unstructured":"Office of National Statistics. Single-year life tables, UK: 1980 to 2020 - Office for National Statistics. 2022."},{"key":"79115","doi-asserted-by":"crossref","unstructured":"Herbert A, Wijlaars L, Zylbersztejn A, Cromwell D, Hardelid P. Data resource profile: Hospital Episode Statistics Admitted Patient Care (HES APC). Int J Epidemiol. 2017; 46(4):1093-1093i.","DOI":"10.1093\/ije\/dyx015"},{"key":"79116","doi-asserted-by":"crossref","unstructured":"Jackson GH, Davies FE, Pawlyn C. Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2019; 20(1):57-73.","DOI":"10.1016\/S1470-2045(18)30687-9"},{"key":"79117","unstructured":"National Institute for Health and Care Excellence. Myeloma: diagnosis and management [NICE Guideline No. NG35]. 2025."},{"key":"79118","doi-asserted-by":"crossref","unstructured":"Pawlyn C, Cairns D, Kaiser M. The relative importance of factors predicting outcome for myeloma patients at different ages: results from 3894 patients in the Myeloma XI trial. Leukemia. 2020; 34(2):604-612.","DOI":"10.1038\/s41375-019-0595-5"},{"key":"79119","doi-asserted-by":"crossref","unstructured":"Blimark CH, Turesson I, Genell A. Outcome and survival of myeloma patients diagnosed 2008-2015. Real-world data on 4904 patients from the Swedish Myeloma Registry. Haematologica. 2018; 103(3):506-513.","DOI":"10.3324\/haematol.2017.178103"},{"key":"79120","doi-asserted-by":"crossref","unstructured":"Moore KLF, Turesson I, Genell A. Improved survival in myeloma patients-a nationwide registry study of 4,647 patients \u226575 years treated in Denmark and Sweden. Haematologica. 2023; 108(6):1640-1651.","DOI":"10.3324\/haematol.2021.280424"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/11992\/78197","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11992\/78751","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11992\/78197","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:08:24Z","timestamp":1794046104000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/11992"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,20]]},"references-count":16,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2024.287095","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3,20]]}}}